Last update: Aug. 17, 2019
Minimal risk for breastfeeding and infant.
S - (+) active enantiomer of ketoprofen with similar structure, pharmacokinetics and anti-inflammatory, anti-allergic and antipyretic properties (Valles 2006, Barbanoj 2001).
Oral administration in three daily doses.
Also used as a gel or cream for topical use.
Since the last update we have not found published data on its excretion in breastmilk. But it is presumed to be similar to that of its enantiomer, ketoprofen, whose excretion in milk is insignificant (Jacqz-Aigrain 2007).
Its high percentage of protein binding and short half-life make it unlikely it will transfer into breastmilk in significant amounts.
Most nonsteroidal anti-inflammatory drugs can increase jaundice, so it is preferable to avoid them during the neonatal period in mothers of infants with jaundice. (Janssen 2000).
Because there is less published information than with other drugs in the same group, safer known alternatives may be preferable, especially during the neonatal period and in cases of prematurity.
The forms of cutaneous application have very low systemic absorption through the skin and are compatible with breastfeeding.
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Confederación Nacional de Pediatría (CONAPEME) from Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM